OTCMKTS:ATBPF Antibe Therapeutics (ATBPF) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free ATBPF Stock Alerts $0.32 -0.01 (-3.05%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.32▼$0.3250-Day Range$0.31▼$0.7852-Week Range$0.24▼$0.89Volume750 shsAverage Volume34,994 shsMarket Capitalization$16.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Antibe Therapeutics alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Antibe Therapeutics Stock (OTCMKTS:ATBPF)Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More ATBPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATBPF Stock News HeadlinesMarch 20, 2024 | businesswire.comAntibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine MeetingMarch 7, 2024 | businesswire.comAntibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine MeetingMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 4, 2024 | marketwatch.comAntibe Therapeutics Shares Sink After Arbitration Case LostFebruary 27, 2024 | benzinga.comAntibe Therapeutics Stock (OTC:ATBPF), Insider Trading ActivityFebruary 14, 2024 | finance.yahoo.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | businesswire.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsNovember 13, 2023 | msn.comAntibe Therapeutics reports Q2 resultsMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… November 9, 2023 | finance.yahoo.comAntibe Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationOctober 20, 2023 | finance.yahoo.comIs Antibe Therapeutics (TSE:ATE) In A Good Position To Deliver On Growth Plans?October 18, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul’s New FormulationSeptember 8, 2023 | finance.yahoo.comAntibe Announces Results of 2023 Annual MeetingAugust 14, 2023 | finance.yahoo.comAntibe Reports Q1 2024 Interim Financial and Operating ResultsJune 29, 2023 | finance.yahoo.comAntibe Reports 2023 Year-End Results and Business HighlightsApril 12, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)April 6, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Wednesday (ATE)March 12, 2023 | finance.yahoo.comAntibe Therapeutics Inc. (ATBPF)February 16, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 15, 2023 | markets.businessinsider.comEchelon Wealth Partners Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 9, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Undervalued Dividend Stocks on TSX (ATE)February 7, 2023 | theglobeandmail.comAntibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)November 22, 2022 | finance.yahoo.comATBPF: On Track to Initiate Phase 2 Trial for Otenaproxesul in 1H23…October 12, 2022 | finance.yahoo.comAntibe Provides Development Update for OtenaproxesulSeptember 9, 2022 | finance.yahoo.comAntibe Announces Results of 2022 Annual MeetingSeptember 6, 2022 | finance.yahoo.comAntibe Academic Collaborator to Present Clinical Data at PAINWeek 2022July 8, 2022 | finance.yahoo.comATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…See More Headlines Receive ATBPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/28/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ATBPF CUSIPN/A CIKN/A Webwww.antibethera.com Phone(416) 922-3460FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.48% Return on Assets-29.07% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual Sales$7.67 million Price / Sales2.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.55Miscellaneous Outstanding Shares52,980,000Free Float48,213,000Market Cap$16.85 million OptionableNot Optionable Beta0.57 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Daniel Marcel Legault J.D. (Age 66)L.L.B., President, CEO, Secretary & Director Comp: $548.19kMr. Alain Wilson M.B.A.MBA, Chief Financial OfficerMr. Scott Curtis C.F.A.M.Eng, Chief Operating OfficerDr. David James Vaughan Ph.D. (Age 74)Chief Development Officer Comp: $299.31kDr. Joseph Stauffer D.O. (Age 58)M.B.A., Chief Medical Officer Comp: $817.09kDr. Ana StegicExecutive Director of Clinical OperationsMs. Christina Cameron B.B.A.Vice President of Investor RelationsMr. Philip SternVice President of CommunicationsMore ExecutivesKey CompetitorsSynthetic BiologicsNYSEAMERICAN:SYNNuCanaNASDAQ:NCNAFlora GrowthNASDAQ:FLGCMIRA PharmaceuticalsNASDAQ:MIRAOncotelic TherapeuticsOTCMKTS:OTLCView All Competitors ATBPF Stock Analysis - Frequently Asked Questions Should I buy or sell Antibe Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATBPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATBPF, but not buy additional shares or sell existing shares. View ATBPF analyst ratings or view top-rated stocks. How have ATBPF shares performed in 2024? Antibe Therapeutics' stock was trading at $0.6820 at the beginning of 2024. Since then, ATBPF stock has decreased by 53.3% and is now trading at $0.3183. View the best growth stocks for 2024 here. Are investors shorting Antibe Therapeutics? Antibe Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 8,900 shares, a decrease of 73.1% from the February 29th total of 33,100 shares. Based on an average daily trading volume, of 88,700 shares, the short-interest ratio is currently 0.1 days. View Antibe Therapeutics' Short Interest. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (OTCMKTS:ATBPF) issued its earnings results on Wednesday, February, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. How do I buy shares of Antibe Therapeutics? Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ATBPF) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.